Johnson & Johnson
JNJ
256.48
-1.97
-0.76%
Johnson & Johnson
US · JNJ
#25 by market cap
Listed 1970
256.48
-1.97
-0.76%
Live - 5344 symbols - heartbeat 447s ago
· 2026-10-08 18:38
Pre-market
257.48
-0.38%
After-hours
256.63
+0.06%
Overnight
257.75
-0.27%
- Market cap
- 618.09B
- P/E (TTM)i
- 29.75
- P/Bi
- 7.27
- EPSi
- 11.03
- Div yieldi
- 2.04%
- 52W posi
- 76%
Reader sentiment
Are you bullish or bearish on JNJ?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 18 analysts
Buy
Avg price target
288.28 +12.4%
Price target rangecurrent 256.48
Low260.00
Avg288.28
High320.00
Buy 78%
Hold 22%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-29 | BofA Securities | -- | HOLD | 278.00 |
| 2026-09-29 | J.P. Morgan | -- | HOLD | 285.00 |
| 2026-09-28 | Scotiabank | -- | BUY | 305.00 |
| 2026-09-22 | Scotiabank | -- | BUY | 305.00 |
| 2026-09-21 | UBS | -- | BUY | 320.00 |
| 2026-09-21 | RBC Capital | -- | BUY | 287.00 |
| 2026-09-18 | Scotiabank | -- | BUY | 305.00 |
| 2026-09-16 | RBC Capital | -- | BUY | 287.00 |
| 2026-09-14 | TD Cowen | -- | BUY | 300.00 |
| 2026-09-11 | DBS | -- | HOLD | 270.00 |
| 2026-09-10 | HSBC | -- | BUY | 320.00 |
| 2026-09-09 | RBC Capital | -- | BUY | 287.00 |
| 2026-09-03 | UBS | -- | BUY | 320.00 |
| 2026-09-02 | UBS | -- | BUY | 320.00 |
| 2026-08-25 | Scotiabank | -- | BUY | 305.00 |
| 2026-08-25 | Goldman Sachs | -- | BUY | 282.00 |
| 2026-08-13 | Citi | -- | BUY | 298.00 |
| 2026-08-05 | Guggenheim | -- | BUY | 287.00 |
| 2026-08-04 | Scotiabank | -- | BUY | 305.00 |
| 2026-08-04 | Citi | -- | BUY | -- |
| 2026-08-03 | Wells Fargo | -- | BUY | 282.00 |
| 2026-08-03 | Morgan Stanley | -- | BUY | 294.00 |
| 2026-08-03 | Goldman Sachs | -- | BUY | 282.00 |
| 2026-07-30 | Scotiabank | -- | BUY | 305.00 |
| 2026-07-28 | Argus Research | -- | BUY | 300.00 |
Quant vs Street three independent views, side by side
StockVane factor grade
B
Momentum strategy signal
Buy
Analyst consensus
Buy
All 3 views agree: bullish.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Improving
2
■ Upgrades■ Downgrades
- 2 upgrades vs 0 downgrades among tracked analyst rating changes.
- Most recent: Leerink Partners moved from Hold to Buy on 2026-05-13.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-05-13 | Leerink Partners | HOLD → BUY | 265.00 |
| 2026-01-28 | Morgan Stanley | HOLD → BUY | 262.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-10-13 | -- | -- | -- |
| 2026/Q2 | 2026-07-15 | -- | ±2.94% | -2.69% (in line) |
| 2026/Q1 | 2026-04-14 | -- | ±3.04% | +0.90% (in line) |
| 2025/Q4 | 2026-01-21 | -- | ±2.79% | -0.09% (in line) |
| 2025/Q3 | 2025-10-14 | -- | ±2.75% | -0.03% (in line) |
| 2025/Q2 | 2025-07-16 | -- | ±2.81% | +6.19% (beat) |
| 2025/Q1 | 2025-04-15 | -- | ±2.90% | -0.48% (in line) |
| 2024/Q4 | 2025-01-22 | -- | ±2.51% | -1.94% (in line) |
| 2024/Q3 | 2024-10-15 | -- | ±2.80% | +1.55% (in line) |
| 2024/Q2 | 2024-07-17 | -- | ±2.81% | +3.69% (beat) |
| 2024/Q1 | 2024-04-16 | -- | ±2.78% | -2.13% (in line) |
| 2023/Q4 | 2024-01-23 | -- | ±2.64% | -1.64% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 18:38:22 · For reference only, not investment advice and not tailored to your situation.